Actinium Presents ATNM-400 Mutation-Agnostic NSCLC Data and PSMA-Independent Prostate Efficacy
Actinium will present three abstracts at SNMMI 2026, showcasing ATNM-400’s potent mutation-agnostic activity in KRAS-mutated NSCLC models and efficacy across PSMA-high, PSMA-low and PSMA-negative prostate cancer. Preclinical radiochemistry data reveal optimized chelator-to-antibody ratios, improving 225Ac-antibody tumor targeting, internalization and pharmacokinetics.
1. Three Abstracts to Be Presented at SNMMI 2026
Actinium will present three ATNM-400 abstracts at the SNMMI 2026 Annual Meeting in Los Angeles from May 30 to June 2, including two posters on oncology applications and one on radioconjugate optimization.
2. Mutation-Agnostic NSCLC Efficacy
Preclinical data in KRAS-mutated non-small cell lung cancer models demonstrate ATNM-400’s potent anti-tumor activity independent of EGFR and KRAS targeted agents, supporting its development as a mutation-agnostic therapy.
3. PSMA-Independent Prostate Cancer Activity
ATNM-400 shows efficacy across PSMA-high, PSMA-low and PSMA-negative prostate cancer models, addressing a key limitation of existing PSMA-targeted radiotherapies and expanding potential patient populations.
4. Radiochemistry Optimization Enhances 225Ac Conjugates
Optimizing the chelator-to-antibody ratio improves tumor targeting, cellular internalization and pharmacokinetics of 225Ac-labeled antibodies, reinforcing Actinium’s proprietary radiochemistry expertise and its pipeline development.